Personalizing Cancer Treatment Recommendations

Founder and CEO

My Personal Therapeutics

Apr 7, 2021PAO-04-22-R221-04

Oncology The Road to 2021 PA TV (video)

At another London stop from the Road to 2021 road trip, Laura Towart, Founder and CEO of My Personal Therapeutics, speaks with Nigel about the company and its vision for personalized cancer treatment.

Developing Cell and Gene Therapies for Rare Oncology Applications

David Alvaro, Ph.D.

Pharma's Almanac

PAO-07-26-PA-10Jul 16, 2026

Tumor-Agnostic

Moving Beyond Tumor Origin: The Rise of Tissue-Agnostic Oncology

David Alvaro, Ph.D.

Pharma's Almanac

PAO-07-26-PA-05Jul 8, 2026

Basket Trials

Basket Trials and the Future of Rare Cancer Research

David Alvaro, Ph.D.

Pharma's Almanac

PAO-07-26-PA-02Jul 2, 2026

Organoids

Data-Centric Organoid Services for Predictive Drug Response and Next-Generation Oncology Research

Seahee Kim, Ph.D.

Samsung Biologics

PAO-06-26-CL-04Jul 1, 2026

Research Collab

10x Genomics and Cleveland Clinic Collaborate in Diagnostic Applications of Single Cell and Spatial Technologies in Bladder Cancer

10x Genomics

PR-06-26-02Jun 17, 2026

Ovarian Cancer

Oncolytic Viruses at a Turning Point: Advancing Olvi-Vec for Advanced Ovarian Cancer

David Alvaro, Ph.D.; Jason Litten, M.D.

Pharma's Almanac

PAO-04-26-CL-03Apr 21, 2026

Ovarian Cancer

Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer

Ernexa Therapeutics

PR-01-26-01Jan 6, 2026

Inducement Grants

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rigel Pharmaceuticals

PR-10-25-NI-04Oct 3, 2025

Collaboration

TegMine Therapeutics Enters Collaboration with Boehringer Ingelheim to Advance Novel 2-Factor Antibody System for Cancer

Tegmine Therapeutics

PR-09-25-NI-05Sep 23, 2025

Cancer Vaccine

Cleveland Clinic to Present Final Phase 1 Results for Anixa Biosciences' Breast Cancer Vaccine at 2025 San Antonio Symposium

Anixa Biosciences

PR-09-25-NI-03Sep 22, 2025

ADCs

Improved Efficacy and Safety Driving Resurging Interest in ADCs

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-09-25-NI-05Sep 22, 2025

Ovarian Cancer

Ovarian Cancer at an Inflection Point: Quantifying the Burden, Closing Gaps, and Accelerating Next-Generation Therapies

David Alvaro, Ph.D.

Pharma's Almanac

PAO-09-25-NI-03Sep 10, 2025

Nice Insight is the market research division of That's Nice LLC, the leading marketing agency serving life sciences.

Explore

About Us Nice Insight That's Nice

Reach Our Team

My Account

Subscribe for the newsletter

Subscribe for the Newsletter

Mobile Navigation

Personalizing Cancer Treatment Recommendations

Related Content

Rare Cancer CGT

Developing Cell and Gene Therapies for Rare Oncology Applications

David Alvaro, Ph.D.

Pharma's Almanac

Tumor-Agnostic

Moving Beyond Tumor Origin: The Rise of Tissue-Agnostic Oncology

David Alvaro, Ph.D.

Pharma's Almanac

Basket Trials

Basket Trials and the Future of Rare Cancer Research

David Alvaro, Ph.D.

Pharma's Almanac

Organoids

Data-Centric Organoid Services for Predictive Drug Response and Next-Generation Oncology Research

Seahee Kim, Ph.D.

Samsung Biologics

Research Collab

10x Genomics and Cleveland Clinic Collaborate in Diagnostic Applications of Single Cell and Spatial Technologies in Bladder Cancer

10x Genomics

Ovarian Cancer

Oncolytic Viruses at a Turning Point: Advancing Olvi-Vec for Advanced Ovarian Cancer

David Alvaro, Ph.D.; Jason Litten, M.D.

Pharma's Almanac

Ovarian Cancer

Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer

Ernexa Therapeutics

Inducement Grants

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rigel Pharmaceuticals

Collaboration

TegMine Therapeutics Enters Collaboration with Boehringer Ingelheim to Advance Novel 2-Factor Antibody System for Cancer

Tegmine Therapeutics

Cancer Vaccine

Cleveland Clinic to Present Final Phase 1 Results for Anixa Biosciences' Breast Cancer Vaccine at 2025 San Antonio Symposium

Anixa Biosciences

ADCs

Improved Efficacy and Safety Driving Resurging Interest in ADCs

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Ovarian Cancer

Ovarian Cancer at an Inflection Point: Quantifying the Burden, Closing Gaps, and Accelerating Next-Generation Therapies

David Alvaro, Ph.D.

Pharma's Almanac

Related Content

Rare Cancer CGT

Developing Cell and Gene Therapies for Rare Oncology Applications

David Alvaro, Ph.D.

Pharma's Almanac

Tumor-Agnostic

Moving Beyond Tumor Origin: The Rise of Tissue-Agnostic Oncology

David Alvaro, Ph.D.

Pharma's Almanac

Basket Trials

Basket Trials and the Future of Rare Cancer Research

David Alvaro, Ph.D.

Pharma's Almanac

Organoids

Data-Centric Organoid Services for Predictive Drug Response and Next-Generation Oncology Research

Seahee Kim, Ph.D.

Samsung Biologics

Research Collab

10x Genomics and Cleveland Clinic Collaborate in Diagnostic Applications of Single Cell and Spatial Technologies in Bladder Cancer

10x Genomics

Ovarian Cancer

Oncolytic Viruses at a Turning Point: Advancing Olvi-Vec for Advanced Ovarian Cancer

David Alvaro, Ph.D.; Jason Litten, M.D.

Pharma's Almanac

Ovarian Cancer

Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer

Ernexa Therapeutics

Inducement Grants

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rigel Pharmaceuticals

Collaboration

TegMine Therapeutics Enters Collaboration with Boehringer Ingelheim to Advance Novel 2-Factor Antibody System for Cancer

Tegmine Therapeutics